Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTIMMUNE: KYV-101 in Autoimmune Diseases
NCT06152172Phase 1Active, not recruiting
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of mivocabtagene autoleucel in idiopathic inflammatory myopathy (IIM), diffuse cutaneous systemic sclerosis (dcSSc), lupus nephritis (LN) and 1 more (4 arms). Primary endpoints: Incidence and severity of Adverse Events in IIM at 24 months, Incidence and severity of Adverse Events in DCSS at 24 months and 2 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
idiopathic inflammatory myopathy (IIM)diffuse cutaneous systemic sclerosis (dcSSc)lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06152172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152172.